Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma
Rothwell, Dominic, G
Moore, D. A.
Frese, Kristopher K
Hubner, Richard A
Valle, Juan W
McNamara, Mairéad G
AffiliationCancer Biomarker Centre, Cancer Research UK Manchester Institute. Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute. Department of Oncology, UCL Cancer Centre. Christie Hospital NHS Foundation Trust. Medical Oncology, The Christie Hospital. Medical Oncology, University of Manchester. Cancer Biomarker Centre, Cancer Research UK Manchester Institute firstname.lastname@example.org.
MetadataShow full item record
AbstractPoorly-Differentiated NeuroEndocrine Carcinomas (PD-NECs) are rare cancers garnering interest as they become more commonly encountered in clinic. This is due to improved diagnostic methods and the increasingly observed phenomenon of 'NE lineage plasticity', whereby non-NeuroEndocrine (non-NE) epithelial cancers transition to aggressive NE phenotypes after targeted treatment. Effective treatment options for patients with PD-NEC is challenging for several reasons. This includes a lack of targetable, recurrent molecular drivers, a paucity of patient-relevant preclinical models to study biology and test novel therapeutics, and the absence of validated biomarkers to guide clinical management. Whilst advances have been made pertaining to molecular subtyping of Small Cell Lung Cancer (SCLC), a PD-NEC of lung origin, Extra-Pulmonary (EP)-PD-NECs remain understudied. This review will address emerging SCLC-like, same-organ non-NE cancer-like and tumour type-agnostic biological vulnerabilities of EP-PD-NECs, with the potential for therapeutic exploitation. The hypotheses surrounding the origin of these cancers and how 'NE lineage plasticity' can be leveraged for therapeutic purposes is discussed. SCLC is herein proposed as a paradigm for supporting progress towards precision medicine in EP-PD-NECs. The aim of this review is to provide a thorough portrait of the current knowledge of EP-PD-NEC biology, with a view to informing new avenues for research and future therapeutic opportunities in these cancers of unmet need.
CitationFrizziero M, Kilgour E, Simpson KL, Rothwell DG, Moore DA, Frese KK, et al. Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma. Clinical Cancer Research. American Association for Cancer Research (AACR); 2022. p. clincanres.3058.2021.
JournalClinical Cancer Research
- Lung neuroendocrine neoplasms: recent progress and persistent challenges.
- Authors: Rekhtman N
- Issue date: 2022 Jan
- Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
- Authors: Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC
- Issue date: 2018 Feb 15
- Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
- Authors: Narayanan D, Mandal R, Hardin H, Chanana V, Schwalbe M, Rosenbaum J, Buehler D, Lloyd RV
- Issue date: 2020 Sep
- Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.
- Authors: Terashima T, Morizane C, Hiraoka N, Tsuda H, Tamura T, Shimada Y, Kaneko S, Kushima R, Ueno H, Kondo S, Ikeda M, Okusaka T
- Issue date: 2012